Fri, Jan 30, 2015, 5:11 AM EST - U.S. Markets open in 4 hrs 19 mins


% | $
Quotes you view appear here for quick access.

Regenerx Biopharmaceuticals Inc. Message Board

  • snogreen snogreen Jun 16, 2011 1:19 PM Flag

    Restasis no#2 drug, AGN

    WOW, I didn't realize this. I just checked Allergan's 10-Q first Q. It turns out that RESTASIS is a VERY important drug for Allergan! It is the companies no# 2 drug in sales. Their BOTOX (anti wrinke, sound familiar?) running 2011 at $364 million oper quarter. RESTASIS is running $162 million. And RESTASIS is growing 20% year over year. That should put RESTASIS sales at about $670 million for 2011. That is pushing Restasis towards the <<<BLOCKBUSTER>>> category....a huge money maker for AGN!

    All that is going to dissappear in LESS than three years for Allergan....cuz I showd that the RESTASIS patent expires.

    Since RESTASIS is the ONLY dry Eye drug approved, and AGN is all set up to sell and market dry eye drugs.....and I checked that AGN has no dry eye drug of in house research.....WHAT should Allergan do? Look for a NEW dry eye drug!

    Sound familiar? Who may have one???

    If RESTASIS is reaaching towards $700 million in sales, it IS almost a blockbuster drug, with hardly any patent life left. If RGRX can should a good pahse 2 of better efficacy that RESTASIS.....and is safe..then it is possible that TB 4 could be a near blockbuster drug too. More than ONE phara would be interested.

    But it al rides on if the Phs 2 can show the efficacy needed..and what the USPO decides. An issued patent is critical to get the interest of AGN.

    One would think more investors would take a shot/gamble/flyer on RGRX. An $18 million market cap? for an almost blockbuster drug category in dry eye...with only ONE drug approved and patent expiring?????

    Leave it to Finkelstein.

0.154-0.001(-0.58%)Jan 29 3:21 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.